Stoke Therapeutics, Inc.
STOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $37 | $9 | $12 | $0 |
| % Growth | 316.3% | -29.2% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $37 | $9 | $12 | $0 |
| % Margin | 100% | 100% | 100% | – |
| R&D Expenses | $89 | $82 | $78 | $54 |
| G&A Expenses | $49 | $41 | $39 | $32 |
| SG&A Expenses | $49 | $41 | $39 | $32 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $138 | $124 | $117 | $86 |
| Operating Income | -$101 | -$115 | -$104 | -$86 |
| % Margin | -277.3% | -1,307.2% | -841.2% | – |
| Other Income/Exp. Net | $12 | $10 | $3 | $0 |
| Pre-Tax Income | -$89 | -$105 | -$101 | -$86 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$89 | -$105 | -$101 | -$86 |
| % Margin | -243.4% | -1,192.5% | -814.7% | – |
| EPS | -1.65 | -2.38 | -2.6 | -2.34 |
| % Growth | 30.7% | 8.5% | -11.1% | – |
| EPS Diluted | -1.65 | -2.38 | -2.6 | -2.34 |
| Weighted Avg Shares Out | 54 | 44 | 39 | 37 |
| Weighted Avg Shares Out Dil | 54 | 44 | 39 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$99 | -$112 | -$103 | -$85 |
| % Margin | -271.4% | -1,279.1% | -828.8% | – |